Aerovate Therapeutics is dedicated to developing innovative therapies for individuals suffering from rare cardiopulmonary diseases, particularly focusing on Pulmonary Arterial Hypertension (PAH). Their lead program, AV-101, is a proprietary dry powder inhaled formulation of imatinib, designed to target the underlying mechanisms of the disease rather than merely alleviating symptoms. This approach aims to address the hyperproliferation of cells in the narrowed arteries of the lungs, which is a critical factor in the progression of PAH. By focusing on the disease drivers, Aerovate seeks to provide meaningful improvements in the health and quality of life for patients affected by this debilitating condition.

The company prides itself on its experienced team, which encompasses a wide range of expertise across the entire drug development process, from initial concept through clinical trials to commercialization. This singular focus on cardiopulmonary diseases enables Aerovate to advance novel therapies that are specifically tailored to meet the needs of patients with rare conditions. Their commitment to innovation and improvement in treatment options reflects a deep understanding of the challenges faced by individuals with PAH, positioning Aerovate as a key player in the field of cardiopulmonary therapeutics.

United States

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Cardiovascular Diseases

Lung Diseases

Aerovate Therapeutics

Pulmonary arterial hypertension

<p class="font_8">Investigational AV-101 is a novel dry powder formulation of the FDA approved therapy imatinib. Dosed specifically for PAH, the AV-101 is designed for delivery by a dry powder inhaler, directly into the lungs to halt the proliferation of cells, improving heart function and everyday health. In a recent Phase 1 clinical trial, Aerovate demonstrated AV-101 was generally well-tolerated by healthy volunteers with no serious adverse events reported.</p>

Aerovate Therapeutics

Company Details